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Purpose: To compare articulated and nonarticulated early walking aids (EWAs) for clinical and quality-of-life outcomes in
transtibial amputees.
Methods: Patients undergoing lower limb amputation in a tertiary-care vascular surgical unit were screened over a 4-year
period. Recruited patients were randomized to receive articulated amputee mobility aid (AMA) or nonarticulated
pneumatic postamputation mobility aid (PPAMA) during early rehabilitation. Primary (10-meter walking velocity) and
secondary clinical (number and duration of physiotherapy treatments during EWA/prosthesis use) and quality-of-life
(SF-36) outcome measures were recorded at five standardized assessment visits. Inter-group and intra-group analyses
were performed.
Results: Two hundred seventy-two patients were screened and 29 transtibial amputees (median age, 56 years) were
recruited (14/treatment arm). No significant difference was seen in demographics and comorbidities at baseline.
Inter-group analysis: Median 10-meter walking velocity was significantly (Mann-Whitney, P  .020) faster in the
PPAMA group (0.245 m/s, interquartile range [IQR] 0.218-0.402 m/s) compared with the AMA group (0.165 m/s;
IQR, 0.118-0.265 m/s) at visit 1. However, there was no difference between the groups at any other visit. Similarly, the
number of treatments using EWAwas significantly (P .045) lower in the PPAMA group (5.0; IQR, 3.5-8.0) compared
with the AMA group (6.0; IQR, 6.0-10.5). No difference was observed between the groups in duration of physiotherapy
or SF-36 domain and summary scores. Intra-group analysis: Both treatment groups showed significant improvement in
10-meter walking velocity (Friedman test; AMA P  .001; PPAMA P  .007); however, other clinical outcomes did not
show any statistically significant improvement. Only physical function domain of SF-36 demonstrated significant
improvement (Friedman test; AMA P  .037; PPAMA P  .029).
Conclusions: There is no difference in clinical and QOL outcomes between articulated and nonarticulated EWAs in
rehabilitation of transtibial amputees. ( J Vasc Surg 2010;52:1564-71.)Lower limb amputation (LLA) is associated with sig-
nificant quality-of-life (QOL) and economic burden for the
patient, society, and health care providers in developed
countries.1,2 The incidence of LLA is highly variable rang-
ing from 22 to 1141 amputations per year per100,000
population over the age of 45 years,3,4 with diabetes mellitus
and peripheral vascular disease (PVD) being the most impor-
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1564tant etiological factors.5 Transtibial amputation (TTA), or
below-knee amputation (BKA), is the most commonly per-
formed major amputation,3,4,6 preferred because of the asso-
ciated improved mobility and reduced energy expenditure in
comparison to transfemoral amputation.7,8 Amputee rehabil-
itation is initiated early to ensure a safe and rapid return to
normal life.9
Early walking aids (EWAs) are routinely used by phys-
iotherapists throughout the world and are an important
part of amputee rehabilitation to aid early mobilization and
gait re-education.9,10 EWAs can be applied in the early
postoperative period to accelerate healing of stump,11,12
reduce complications,13 and facilitate early fitting of defin-
itive prosthesis.14,15 There are several different EWAs cur-
rently used in patients with TTA ranging from simple pylon
structures with adjustable sockets, pneumatic splints, and
rigid frames to more complex articulated devices.16-18 In
the United Kingdom, the two most popular walking aids
include the pneumatic postamputation mobility aid
(PPAMA)19 and the amputee mobility aid (AMA).16 The
articulation in AMA allows movement at the knee joint
during walking unlike the rigid construct of PPAMA.
PPAMA remains the most commonly used EWA world-
wide due to easy availability, low cost, and simplicity of
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vidually;16,18 however, this is the first study to directly
compare these two EWAs in terms of clinical and QOL
outcomes and rehabilitation duration. We hypothesized
that the articulated AMA offers clinical and QOL advan-
tage over the nonarticulated PPAMA.
METHODS
The trial was approved by local research committee and
conducted in a tertiary care university hospital. Patients
admitted to the vascular surgical unit for unilateral tran-
stibial amputation were screened for eligibility for inclusion
in the study. The inclusion and exclusion criteria for the
study are given in Table I. Eligible patients were contacted
after the decision for amputation was made, evaluated by
trained physiotherapists for assessment of rehabilitation
potential, and were invited to take part in the study, if
suitable. Emergency surgery patients were excluded due to
unavailability of presurgical specialist physiotherapy assess-
ment service outside normal working hours. Informed con-
sent was obtained from the patients willing to participate in
the study. Participants were randomized prior to surgery to
receive one of the two EWAs using sealed envelopes. Tran-
stibial amputations were performed by consultant vascular
surgeons using standard predefined technique using long
posterior flap and myoplasty ensuring a minimum stump
length of 10 cm from the tibial tuberosity.
Intervention
Early physiotherapy was encouraged and EWA use was
commenced when the patients attended the physiotherapy
unit and were able to tolerate EWA, after being discharged
Table I. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
● Unilateral transtibial
amputation
● Expected to receive a
functional prosthesis
● At least 18 years of age
● Able to tolerate and use
EWA
● Able to walk a distance
of 4 meters
● Willing to attend hospi-
tal-based rehabilitation
program following pros-
thesis fitting
● Meet the manufacturer’s
recommendation for
using the EWAs
● Major amputation of contralateral
limb
● Not expected to receive a func-
tional prosthesis (severe debilitat-
ing medical illness eg, severe
dementia, fixed flexion deformity,
severe Parkinson’s disease, heart
failure, etc)
● Unable to walk prior to amputa-
tion due to medical condition eg,
spinal injury, stroke, rheumatoid
arthritis
● Unable to follow instructions
and/or participate in a rehabilita-
tion program (not resident in the
hospital catchments area)
● Unable to consent to take part in
the study
● Do not meet the manufacturer’s
recommendations for using the
EWAs
EWA, Early walking aids.
This table represents the inclusion and exclusion criteria for the trial.from the hospital following complete recovery from theirsurgery. Physiotherapy continued after the delivery of de-
finitive prosthesis. The number of physiotherapy treat-
ments administered was variable depending on individual
patient needs. The patients used one of the two EWAs:
Pneumatic post amputation mobility aid (PPAMA).
PPAMA, developed in 1978,18,19 is the most commonly
used EWA in the United Kingdom.16 This nonarticulated
EWA consists of a pneumatic bag, a supporting frame, and
a rocker foot (Fig 1). As there is no articulation, the
biological knee is kept in extension while walking.
Amputee mobility aid (AMA). AMA, developed in
1993, incorporates a simple hinge mechanism to replicate a
more natural movement (active flexion and extension) of
the knee16 (Fig 2).
Assessments
All assessments were performed in a specialist amputee
rehabilitation physiotherapy unit staffed by physiothera-
pists with clinical expertise in this area. All patients were
assessed to ensure optimal fit of either their EWA or pros-
thesis at each visit. As the number of physiotherapy sessions
received by each patient was variable, five standard time
points were identified for assessment of patients. These
included time of initial fitting of EWA (visit 1), final reha-
bilitation session while using EWA (visit 2), time of first use
of definitive prosthesis (visit 3), 2 weeks following fitting of
definitive prosthesis (visit 4), and at discharge from active
physiotherapy (visit 5) ensuring the safe use of prosthesis by
Fig 1. The Pneumatic Post Amputation Mobility Aid (PPAMA -
left) and inflatable residuum bag (right). (Image reproduced with
permission of Ortho Europe Ltd, Alton, UK. www.ortho-
europe.co.uk.)the patient.
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All outcome measures were recorded at each of the five
assessment visits.
Primary. Ten-meter walking velocity; at each visit, all
patients were asked to perform a 10-meter walk from a
standing start. Patients walked from the starting point for 5
meters using parallel bars for support, took a 180 degree
turn, and walked back to the starting point. The time taken
to complete this test was recorded using a digital stopwatch
using standardized technique by a member of the research
team, and 10-meter walking velocity was calculated.
Secondary. (1) Generic QOL analysis; using the Short
Form 36 instrument, which comprises 36 items that are
summarized to produce eight domain scores namely phys-
ical function (PF), role limitation physical problems (RP),
bodily pain (BP), general health (GH), vitality (V), social
function (SF), role limitation due to emotional problems
(RE), and mental health (MH). Domain scores are
grouped together to yield two summary scores namely
physical component summary (PCS) and mental compo-
nent summary (MCS). This instrument is valid, reliable,
and responsive in this particular population.23
(2) Total number of physiotherapy treatments; including
the number of physiotherapy sessions prior to and
during EWA use and the number of sessions during
prosthesis use.
(3) Physiotherapy duration in days while using EWA, de-
Fig 2. The articulated Amputee Mobility Aid (AMA). (Image
reproduced with permission of Ortho Europe Ltd, Alton, UK.
www.orto-europe.co.uk.)finitive prosthesis, and overall duration.Statistical analysis
Data were recorded using Microsoft Excel 2003 (Mi-
crosoft Corporation, Redmond, Wash) and analyzed using
SPSS 16.0 (SPSS Corporation, Chicago, Ill). All continu-
ous variables were checked for normality using histograms
and normality tests (Kolmogorov–Smirnoff test). Hypoth-
esis testing was performed using nonparametric tests for
inter-group (Mann-Whitney test) and intra-group (Fried-
man test) analyses of continuous variables. Categorical
variables were analyzed using Fischer exact test. Adjust-
ments were made to the P values for multiple testing using
Bonferroni method.
Sample size calculation
There were no previous studies reported in the litera-
ture comparing walking velocities in TTA patients using
EWAs. We, therefore, performed sample size calculation
using studies that reported 10-meter walking velocities in
transtibial amputees using definitive prosthesis.24,25 The
first study reported the mean velocity of 0.28 m/s at week
1 improving to 0.51m/s at week 4 with rehabilitation (82%
improvement),24 while the second study reported a mean
velocity of 0.78 m/s.25 We used the higher mean velocity
available with pooled standard deviation from the two
studies. Considering the evidence of 82% improvement in
the first study, we calculated the sample size for mean
velocity of 0.78 m/s with pooled SD of 0.33; the required
sample size for 90% power and 5% significance was six
patients in each group. We then looked at the difference in
highest mean velocities as quoted in the two studies. This
showed a 53% difference in the two values (0.51 m/s vs
0.78m/s). We used this difference to guide our sample size
calculations, thus, using the highest mean velocity (0.78
m/s) and a pooled standard deviation (0.33), we required
13 patients in each arm to detect a 50% difference in
10-meter walking velocity at discharge for 90% power and
an alpha of 0.05.
RESULTS
Two hundred seventy-two amputations were per-
formed over a three and a half year period between Septem-
ber 2005 and April 2009. Only 10.7% (n  29) of these
patients were eligible for inclusion, consented to partici-
pate, and were randomized to one of the two treatment
arms. Three patients were lost to follow-up giving us a total
of 13 patients in each treatment arm as per requirement
(CONSORT diagram, Fig 3).
Inter-group analysis
There was no difference between the two groups for
age, height, weight, indication for surgery, comorbidities,
hospital stay, and time to commencement of ambulation
postsurgery (Table II).
Ten-meter walking velocity (Table III). At visit 1,
patients using the PPAMA had significantly faster 10-meter
walking velocity than patients using the EWA. However, at
iagram
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meter walking velocity between the two groups.
Number of physiotherapy treatments (Table IV).
There was no statistically significant difference in the num-
ber of physiotherapy treatments received by patients in
either group prior to EWA use and during definitive pros-
thesis use. However, the median number of treatments
received by patients using the PPAMA was significantly
lower (P .05) than those using the AMAduring the EWA
use.
Duration of physiotherapy treatment (Table IV). The
median duration of physiotherapy treatment during EWA
and prosthesis use was shorter for patients using PPAMA
compared with those using the AMA. Conversely, the total
duration of physiotherapy was shorter in the AMA group.
However, these differences were not statistically significant.
QOL outcomes (Figs 4 and 5). There were no sta-
tistically significant differences between the two treatment
arms in any of the SF-36 physical or mental health domain
at any time point. Consequently, there was no difference
seen in the physical and mental component summary
scores.
Intra-group analysis (Tables III and V; Figs 4 and 5)
Both groups demonstrated statistically significant im-
provements in the 10-meter walk velocity and in the SF-36
physical function domain over time (Friedman test, P 
.05). No statistically significant difference was observed in
any other SF-36 domain and summary scores in any treat-
Fig 3. CONSORT dment arm.DISCUSSION
Our study has clearly demonstrated that there is no
difference between articulated and nonarticulated EWAs
for clinical and QOL outcomes in transtibial amputees.
This is the first reported study to analyze and compare these
outcomes at length. Although a previous study compared
interface pressures between the two EWAs and range of
movement of the AMA mechanical knee and the amputee
knee joint,16 no effort was made to compare other clinical
outcomes including duration of rehabilitation or walking
times.
Ten-meter walking velocity is a well-established out-
come measure25,26 and has been used previously to dem-
onstrate functional ability in transtibial amputees.24,27 It is
affected by age,28 lower limb strength,29 vascular status of
the contralateral limb,30 balance,31 and energy expendi-
ture.32 In our study, although the 10-meter walking veloc-
ity improved significantly within each group and was clearly
faster in the PPAMA group at visit 1, there was an interest-
ing difference in trend. Patients with AMAs took longer to
complete the walk at the first visit; however, they improved
progressively in all later visits with a shorter walking time at
each subsequent visit. The fastest velocity was recorded at
the last visit in this group. Conversely, patients in the
PPAMA group were quicker to start at visit 1 and improved
in visit 2, however, they were considerably slower with the
definitive prosthesis when using it for the first time (visit 3).
This improved in subsequent visits but remained slower
compared with the AMA group. The articulation in AMAs
can possibly explain this phenomenon. Patients using
of trial participants.AMAs initially take longer due to active control of knee
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re-education. However, once learned, they progressed
swiftly without any problems. On the other hand, the rigid
construct of PPAMA made it relatively easy to use on the
first visit. However, active movement of the knee while
walking was experienced when the patients used the defin-
Table II. Inter-group analysis – Basic demographics, indic
Variable AMA (n  13)
Age (y)1 57.00 (41.50 to 67.
Male:female 12:01
Right:left 07:06
Height (meters)1 1.77 (1.71 to 1.83
Weight (kg)1 77.0 (72.70 to 99.
Indication for surgery2
Ischemia 3 (23.1)
Neuropathic painful foot 3 (23.1)
Infected diabetic foot 5 (38.4)
Venous ulcers 1 (7.7)
Neoplasia 1 (7.7)
Comorbidities2
Hypertension 1 (7.70)
Diabetes 5 (38.5)
Hypercholesterolemia 0 (0.0)
Ischemic heart disease 2 (15.4)
CVA 2 (15.4)
COPD/asthma 2 (15.4)
Postsurgery1
Hospital stay (d) 18.00 (8.50 to 32.0
Time to ambulation (d) 15.50 (10.50 to 33.
AMA, Amputee mobility aid; COPD, chronic obstructive pulmonary diseas
aid.
This table represents basic demographics, indications for surgery, comorbidi
are represented as median (interquartile range) and categorical variables ar
Mann-Whitney, and Fischer exact tests.
1Median (IQR).
2N (%).
aMann-Whitney test.
bFischer exact test.
c2 test for trend.
Table III. Primary outcome –10-meter walking velocity
10-meter
walk
velocity
(meters/s)
Treatment arm
P
valueaAMA PPAMA
Visit 1 0.165 (0.118-0.265) 0.245 (0.218-0.402) .020
Visit 2 0.411 (0.373-0.536) 0.481 (0.307-0.761) .412
Visit 3 0.561 (0.447-0.667) 0.426 (0.332-0.618) .974
Visit 4 0.822 (0.569-0.959) 0.800 (0.495-1.104) .305
Visit 5 1.083 (0.642-1.134) 0.790 (0.742-1.127) .605
AMA,Amputeemobility aid; PPAMA, pneumatic post amputationmobility
aid.
This table represents the 10-meter walking velocity for both groups at all
time points. All values are presented as median (interquartile range). P values
represent inter-group comparisons using Mann-Whitney test. All significant
comparisons are represented in bold font.
aMann-Whitney test.itive prosthesis for the first time. This resulted in slowerwalking times during this session, however, this improved
in all subsequent sessions. Eventually, there was no signif-
icant statistical difference between the two groups when
ambulating with the definitive prosthesis at discharge from
active physiotherapy. Thus, gait re-education pattern was
different for the groups without any significant effect on
clinical outcome.
There is reported evidence in literature to support
subtle differences between the two EWAs in knee angles
and gait pattern during gait re-education as a result of
physiotherapy and rehabilitation.16 We have previously an-
alyzed the kinematic gait adaptation during rehabilitation
comparing the two EWAs and have reported some differ-
ences in cadence, early temporal-spatial adaptation, and
gait pattern, which persisted during transfer to functional
prosthesis; however, both groups demonstrated similar
rates and levels of improvement in walking performance
reaching an acceptable level of walking activity.33 We have
now demonstrated, with this current study, that articula-
tion of an EWA does not reduce the duration of physio-
therapy, or the number of physiotherapy treatments prior
to EWA and during definitive prosthesis use. In fact, these
parameters were shorter in the nonarticulated EWA group;
however, failure to reach statistical significance is a likely
ns, comorbidities, and postoperative parameters
reatment arm
P valuePPAMA (n  13)
55.00 (40.50 to 65.50) .817a
10:03 .593b
06:07 1.000b
1.75 (1.61 to 1.85) .572a
88.0 (70.60 to 94.40) .918a
5 (38.4) .709c
4 (30.8)
4 (30.8)
0 (0.0)
0 (0.0)
5 (38.5) .160b
4 (30.8) 1.000b
3 (23.1) .220b
3 (23.1) 1.000b
0 (0.0) .480b
1 (7.7) 1.000b
12.00 (8.00 to 26.50) .472a
15.00 (10.50 to 33.00) .978a
A, cerebrovascular accident; PPAMA, pneumatic post amputation mobility
nd postsurgery parameters for the trial participants. All continuous variables
esented as N (%). Similarly, P values are generated using 2 test for trend,atio
T
00)
)
50)
0)
50)
e; CV
ties, a
e reprconsequence of a smaller sample size. Nonetheless, we can
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between the two EWAs have no bearing on the clinical
outcome.
QOL outcomes are as important as clinical endpoints
and are now reported routinely in all clinical trials.34 There
is a relative dearth of studies reporting QOL outcomes in
EWA trials and ours is the only one to date to investigate
these outcomes. The significant improvement observed in
physical function in both treatment arms is hardly surpris-
ing, as this is the most relevant domain of SF-36. However,
the lack of any difference between the treatment arms in
0
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40
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80
10
0
AMA PPAMA
SF36 − Physical Function
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
0
20
40
60
80
10
0
AMA PPAMA
SF36 − Bodily Pain
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Fig 4. This figure represents the inter- and intra-grou
represented by a box and whisker plot. The line in the m
interquartile range (IQR), and the whiskers represent up
represented by an asterisk.
Table IV. Secondary clinical outcome measures
Variable AM
No. of treatments prior to EWA 1.50 (1.00-
Time using EWA (d) 38.00 (18.00
No. of treatments during EWA use 6.0 (6.00-
Time using prosthetic limb (d) 52.50 (39.00
No. of treatments during prosthesis use 7.50 (5.00-
Total duration of physiotherapy (d) 92.00 (74.50
AMA, Amputee mobility aid; PPAMA, pneumatic post amputation mobilit
This table represents the secondary outcome measures for both groups. All v
comparisons using Mann-Whitney test. All significant comparisons are repr
aMann-Whitney test.domain or summary scores should be interpreted withcaution for a number of reasons. First, the sample size
calculations were performed for clinical outcomes and,
therefore, perhaps the study was inadequately powered to
detect QOL differences. Second, we used a generic QOL
instrument that is influenced by overall health and circum-
stances, when perhaps a disease-specific instrument may
have been more appropriate and responsive to QOL
changes in this situation. Nonetheless, these results provide
basis for further investigations in future trials.
The economic implications of the findings of this trial
are far reaching. EWAs are used extensively and routinely in
0
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80
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0
AMA PPAMA
SF36 − Role Physical
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
0
20
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80
10
0
AMA PPAMA
SF36 − General Health
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
mparison of the physical health domains of the SF-36
of the box represents the median, the box represents the
5 times the IQR. Outliers beyond 1.5 times the IQR are
Treatment arm
P valueaPPAMA
) 2.00 (0.50-3.50) .824
25) 21.00 (12.00-39.00) .281
0) 5.00 (3.50-8.00) .045
75) 39.00 (27.50-63.50) .590
0) 7.00 (5.00-13.00) .956
.00) 112.00 (67.50 – 148.00) .590
re presented as median (interquartile range). P values represent inter-group
d in bold font.p co
iddle
to 1.A
5.25
-56.
10.5
-66.
11.5
-213
y aid.
alues a
esenteall postamputation rehabilitation programs.9,10 The artic-
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order only) compared with the nonarticulated PPAMA
(£881/$1378). Although we have not performed a formal
calculation of utilities and costs in this study, we have
demonstrated that there is no clinical or QOL advantage of
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Fig 5. This figure represents inter- and intra-group com
by a box and whisker plot. The line in the middle of the b
range (IQR) and the whiskers represent up to 1.5 times
by an asterisk.
Table V. Intra-group analysis: Friedman test for
continuous variables
Variable
Significance (P value)
AMA PPAMA
10-meter walk time .001 .007
Physical function .037 .029
Role physical .572 .175
Bodily pain .695 .919
General health .768 .958
Vitality .162 .117
Social function .131 .232
Role emotional .277 1.000
Mental health .308 .321
Physical component summary .284 .086
Mental component summary .801 .615
AMA,Amputeemobility aid; PPAMA, pneumatic post amputationmobility
aid.
This table represents intra-group comparison for clinical and QOL (SF-36)
outcome measures in both groups. P values are generated using Friedman
test. All significant comparisons are represented in bold font.using one over the other. Thus, routine use of more expen-sive AMA is likely to incur additional costs without signif-
icant clinical advantage. Therefore, AMA should only be
reserved for situations where PPAMA is unsuitable or un-
available as per usual practice in most of the rehabilitation
centers. A full economic evaluation needs to be formally
undertaken to compare the cost-effectiveness of these
EWAs in the future to aid decision makers in health care for
policy making and application.
CONCLUSIONS
EWAs are useful adjuncts in gait re-education and
rehabilitation of transtibial amputees and help to improve
the walking velocity and physical function. However, pres-
ence of articulation to aid early knee joint movement
(AMA) does not offer any clinical or QOL advantage over
nonarticulated PPAMA in these patients. Further studies
are required to evaluate any disease-specific QOL differ-
ences and the full economic impact of using different
EWAs.
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